Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 2
1978 1
1979 2
1980 1
1981 2
1982 2
1983 1
1987 1
1989 1
1990 1
1993 2
1994 1
1995 1
1996 1
1997 1
1998 2
1999 6
2000 3
2001 2
2002 3
2003 2
2004 4
2005 10
2006 5
2007 6
2008 2
2009 2
2010 6
2011 8
2012 8
2013 6
2014 6
2015 9
2016 9
2017 12
2018 6
2019 8
2020 15
2021 20
2022 16
2023 18
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.
Di Federico A, Ricciotti I, Favorito V, Michelina SV, Scaparone P, Metro G, De Giglio A, Pecci F, Lamberti G, Ambrogio C, Ricciuti B. Di Federico A, et al. Curr Oncol Rep. 2023 Sep;25(9):1017-1029. doi: 10.1007/s11912-023-01436-y. Epub 2023 Jun 28. Curr Oncol Rep. 2023. PMID: 37378881 Review.
Off-target acquired resistance can derive from activating mutations in KRAS downstream pathway (e.g., MEK1), acquired oncogenic fusions (EML4-ALK, CCDC176-RET), gene level copy gain (e.g., MET amplification), or oncogenic alterations in other pro-proliferative and a …
Off-target acquired resistance can derive from activating mutations in KRAS downstream pathway (e.g., MEK1), acquired oncogenic fusio …
Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.
Man KKC, Häge A, Banaschewski T, Inglis SK, Buitelaar J, Carucci S, Danckaerts M, Dittmann RW, Falissard B, Garas P, Hollis C, Konrad K, Kovshoff H, Liddle E, McCarthy S, Neubert A, Nagy P, Rosenthal E, Sonuga-Barke EJS, Zuddas A, Wong ICK, Coghill D; ADDUCE Consortium. Man KKC, et al. Lancet Psychiatry. 2023 May;10(5):323-333. doi: 10.1016/S2215-0366(23)00042-1. Epub 2023 Mar 20. Lancet Psychiatry. 2023. PMID: 36958362
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Ramaiya N, Presley CJ, Owen DH, Abou Alaiwi S, Nassar A, Ricciuti B, Lamberti G, Bersanelli M, Casartelli C, Buti S, Marchetti P, Giusti R, Filetti M, Vanella V, Mallardo D, Macherla S, Sussman TA, Botticelli A, Galetta D, Catino A, Pizzutilo P, Genova C, Dal Bello MG, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Choueiri TK, Johnson DB, Marron TU, Wang Y, Naqash AR. Nebhan CA, et al. JAMA Oncol. 2021 Dec 1;7(12):1856-1861. doi: 10.1001/jamaoncol.2021.4960. JAMA Oncol. 2021. PMID: 34734989 Free PMC article.
Among all 928 patients, 383 (41.3%) experienced 1 irAE(s), including 113 (12.2%) that were reported to be grade (G) 3 to 4 based on Common Terminology Criteria for Adverse Events (version 5.0). ...
Among all 928 patients, 383 (41.3%) experienced 1 irAE(s), including 113 (12.2%) that were reported to be grade (G) 3 to 4 based on C …
New Horizons of Cementless Total Knee Arthroplasty.
Polizzotti G, Lamberti A, Mancino F, Baldini A. Polizzotti G, et al. J Clin Med. 2023 Dec 30;13(1):233. doi: 10.3390/jcm13010233. J Clin Med. 2023. PMID: 38202240 Free PMC article. Review.
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Elkrief A, Riccuiti B, Alessi JV, Fei T, Kalvin HL, Egger JV, Rizvi H, Thummalapalli R, Lamberti G, Plodkowski A, Hellmann MD, Kris MG, Arcila ME, Baine MK, Rudin CM, Lito P, Ladanyi M, Schoenfeld AJ, Riely GJ, Awad MM, Arbour KC. Elkrief A, et al. Oncologist. 2023 Nov 2;28(11):978-985. doi: 10.1093/oncolo/oyad197. Oncologist. 2023. PMID: 37589215 Free PMC article.
Sol-Gel Dipping Devices for H2S Visualization.
Strianese M, Ferrara G, Vykhovanets V, Blal N, Guarnieri D, Landi A, Lamberti M, Peluso A, Pellecchia C. Strianese M, et al. Sensors (Basel). 2023 Feb 10;23(4):2023. doi: 10.3390/s23042023. Sensors (Basel). 2023. PMID: 36850620 Free PMC article.
In this contribution we report the synthesis and full characterization, via a combination of different spectroscopies (e.g., (1)H NMR, UV-vis, fluorescence, MALDI), of a new family of fluorescent zinc complexes with extended pi-conjugated systems, with the final aim of set …
In this contribution we report the synthesis and full characterization, via a combination of different spectroscopies (e.g., (1)H NMR …
Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?
Ricco G, Andrini E, Siepe G, Mosconi C, Ambrosini V, Ricci C, Casadei R, Campana D, Lamberti G. Ricco G, et al. Int J Mol Sci. 2021 Sep 30;22(19):10629. doi: 10.3390/ijms221910629. Int J Mol Sci. 2021. PMID: 34638968 Free PMC article. Review.
In addition, novel insights into tumor biology and newly developed treatments (e.g., immune checkpoint inhibitors) that dramatically improved outcomes in the advanced setting are being investigated in earlier stages with promising results. ...
In addition, novel insights into tumor biology and newly developed treatments (e.g., immune checkpoint inhibitors) that dramatically …
195 results